A CLINICAL TRIAL TO FIND OUT THE TREATMENT OF DIABETIC POLYNEUROPATHY BY AN AYURVEDIC MEDICINE

A CLINICAL STUDY ON THE MANAGEMENT OF DIABETIC POLYNEUROPATHY WITH DASHAMOOLADI RASAYANA COMPOUND

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/07/001885

Enrollment

Registered

2011-07-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diabetic Polyneuropathy

Interventions

Intervention1: Tab. Dashamooladi Rasayana Compound: 3 tablets of 500mg twice daily

8 weeks Control Intervention1: Cap. Pregabalin and Methylcobalamin: One capsule containing 75mg of Pregabalin and 750 mcg of Methylcobalamin

OD for 8 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Metabolically stable type II diabetic patients with symptomatic diabetic sensorimotor polyneuropathy (DSPN) of either sex between the age group of 35-70 years with written informed consent.

Exclusion criteria

Exclusion criteria: Patients who are insulin dependent. Patients with other metabolic and endocrinal disorders. Patients with other causes of Polyneuropathy. Patients suffering from infectious diseases. Patients with non healing ulcer/ulcers. Patients with Diabetic Polyneuropathy in stage N3

Design outcomes

Primary

Measure	Time frame
Changes in Neuropathy Symptom Score (NSS) and Michigan Neuropathy Screening Instrument (MNSI)Timepoint: 0, 8 weeks	—

Secondary

Measure	Time frame
Agni Bala; Deha Bala; Chetas Bala; WHO Quality of Life (WHO QoL) BREFTimepoint: 0, 8 weeks	—

Countries

India

Contacts

Public ContactDrMA Santwani

baghelayu@rediffmail.com0288-2552014

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026